A multimodal study of a first episode psychosis cohort: potential markers of antipsychotic treatment resistance

Psychosis and Schizophrenia

Association of Hippocampal Atrophy With Duration of Untreated Psychosis and Molecular Biomarkers During Initial Antipsychotic Treatment of First-Episode Psychosis

JAMA Psychiatry.

Goff DC, Zeng B, Ardekani BA, Diminich ED, Tang Y, Fan X, Galatzer-Levy I, Li C, Troxel AB, Wang J

doi: 10.1001/

Psychosis and Schizophrenia

Staged treatment and acceptability guidelines in early psychosis study (STAGES): A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first-episode psychosis with low-risk of self-harm or aggression. Study protocol and baseline characteristics of participants

Early Interv Psychiatry.

O'Donoghue B, Francey SM, Nelson B, Ratheesh A, Allott K, Graham J, Baldwin L, Alvarez-Jimenez M, Thompson A, Fornito A, Polari A, Berk M, Macneil C, Crisp K, Pantelis C, Yuen HP, Harrigan S, McGorry P

doi: 10.1111/eip.12716.

Psychosis and Schizophrenia

Effect of delaying treatment of first-episode psychosis on symptoms and social outcomes: a longitudinal analysis and modelling study

Lancet Psychiatry.

Drake RJ, Husain N, Marshall M, Lewis SW, Tomenson B, Chaudhry IB, Everard L, Singh S, Freemantle N, Fowler D, Jones PB, Amos T, Sharma V, Green CD, Fisher H, Murray RM, Wykes T, Buchan I, Birchwood M

doi: 10.1016/S2215-0366(20)30147-4.

Psychosis and Schizophrenia

The relationship between cortical glutamate and striatal dopamine in first-episode psychosis: a cross-sectional multimodal PET and magnetic resonance spectroscopy imaging study

Lancet Psychiatry.

Jauhar S, McCutcheon R, Borgan F, Veronese M, Nour M, Pepper F, Rogdaki M, Stone J, Egerton A, Turkheimer F, McGuire P, Howes OD

doi: 10.1016/S2215-0366

Psychosis and Schizophrenia

Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study

Lancet Psychiatry.

Morrison AP, Pyle M, Maughan D, Johns L, Freeman D, Broome MR, Husain N, Fowler D, Hudson J, MacLennan G, Norrie J, Shiers D, Hollis C, James A, MAPS group.

doi: 10.1016/S2215-0366(20)30248-0.

Psychosis and Schizophrenia

Prevalence and clinical characteristics of serum neuronal cell surface antibodies in first-episode psychosis: a case-control study.

Lancet Psychiatry.

Lennox BR, Palmer-Cooper EC, Pollak T, Hainsworth J, Marks J, Jacobson L, Lang B, Fox H, Ferry B, Scoriels L, Crowley H, Jones PB, Harrison PJ, Vincent A

doi: 10.1016/S2215-0366

Psychosis and Schizophrenia

Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study

Psychol Med.

Quattrone D, Di Forti M, Gayer-Anderson C, Ferraro L, Jongsma HE, Tripoli G, La Cascia C, La Barbera D, Tarricone I, Berardi D, Szöke A, Arango C, Lasalvia A, Tortelli A, Llorca PM, de Haan L, Velthorst E, Bobes J, Bernardo M, Sanjuán J, Santos JL, Arrojo M, Del-Ben CM, Menezes PR, Selten JP; EU-GEI WP Group, Jones PB, Kirkbride JB, Richards AL, O'Donovan MC, Sham PC, Vassos E, Rutten BP, van Os J, Morgan C, Lewis CM, Murray RM, Reininghaus U

doi: 10.1017/

Anxiety and DepressionPsychosis and Schizophrenia

Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial

Lancet Psychiatry.

Pagsberg AK, Jeppesen P, Klauber DG, Jensen KG, Rudå D, Stentebjerg-Olesen M, Jantzen P, Rasmussen S, Saldeen EA, Lauritsen MG, Bilenberg N, Stenstrøm AD, Nyvang L, Madsen S, Werge TM, Lange T, Gluud C, Skoog M, Winkel P, Jepsen JRM, Fagerlund B, Correll CU, Fink-Jensen A

doi: 10.1016/S2215-

EpilepsyPsychosis and Schizophrenia

Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study

Lancet Psychiatry.

Kahn RS, Winter van Rossum , Leucht S, McGuire P, Lewis SW, Leboyer M, Arango C, Dazzan P, Drake R, Heres S, Díaz-Caneja CM, Rujescu D, Weiser M, Galderisi S, Glenthøj B, Eijkemans MJC, Fleischhacker WW, Kapur S, Sommer IE; OPTiMiSE study group

doi: 10.1016/

Related content

Association of Hippocampal Atrophy With Duration of Untreated Psychosis and Molecular Biomarkers During Initial Antipsychotic Treatment of First-Episode Psychosis

Effect of delaying treatment of first-episode psychosis on symptoms and social outcomes: a longitudinal analysis and modelling study

The relationship between cortical glutamate and striatal dopamine in first-episode psychosis: a cross-sectional multimodal PET and magnetic resonance spectroscopy imaging study

Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study

Prevalence and clinical characteristics of serum neuronal cell surface antibodies in first-episode psychosis: a case-control study.

Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study

Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial

Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study